Precise genome editing: the key to a CRISPR drug discovery pipeline? By Dr. J. D. Wrigley, Dr M Maresca, Dr K Birmingham, Dr M Bohlooly-Y and Dr L M. Mayr From the pioneering days of Watson and Crick in 1953, to completion of the human genome project in… Read More
Therapeutic Drug Repurposing, Repositioning and Rescue Part II: Business Review By Dr Stephen Naylor, David M. Kauppi and Judge M. Schonfeld There is an emerging consensus that the impact of Drug Repurposing, Repositioning and Rescue (DRPx) on the pharmaceutical industry is real and sustainable. Read More
Immunotherapy: The coming of age of cancer immunotherapy as a treatment paradigm By Dr Jean Pierre Wery As the oncology drug development landscape has evolved, so too have the processes, methods and equipment used in the fight against cancer. Traditional treatments such as chemotherapy and radiation therapy are… Read More
Restucturing Proteomics: The rise of next-generation affinity reagents By Dr Paul Ko Ferrigno & Dr Jane McLeod The ability of antibodies to bind their target proteins with some degree of specificity has elevated them to being among the most useful tools in biology and medicine, with a market… Read More
Vector Mediated Therapeutics Based Upon DNA-Directed RNA Interference By Dr David Suhy A decade and a half after being first described to occur in mammalian cells, numerous trials are indicating that RNA interference can be harnessed to treat human disease. This article argues that positive results are… Read More
Automated Patch Clamping Finally Achieves High Throughput By Dr John Comley Two new third-generation automated patch clamp (APC) systems capable of high throughput processing (10,000 data points per eight-hour day) and full robotic integration have been recently launched. The resulting wider choice of primarily 384 APC systems has… Read More
Advancing the Promise of Therapeutic Genomic Editing By Dr Morgan L. Maeder and Dr David Bumcrot The development of genome editing technology is revolutionising the study of gene function and has the potential to usher in a new class of therapeutics for a broad range of diseases. Read More
Reconfiguring Drug Discovery Through Innovative Partnerships By Dr Robert Grundy, Iain James, Chas Bountra and Timothy Harrison Attrition rates in drug discovery and development remain stubbornly high, despite large investments by the pharmaceutical industry. The cost of developing a new drug has been estimated at between $1.3 billion… Read More
By Dr Scott R. Burger, Louis Juliano, and Dr Wenshi Wang For more than two decades, the biotechnology and pharmaceutical industries have been working to unlock the great potential of cell therapy, which uses products composed of living, functional cells to mediate the therapeutic effect. Read More
Best Practices In Biobanking By Kiara W. Biagioni Biobanks or biorepositories are facilities that collect, process, store and distribute biospecimens and associated data, mainly for biological and medical research. They constitute a crucial resource, supporting cutting-edge investigation in fields such as oncology, genomics and personalised medicine, and the… Read More
Oncology Target Discovery by RNAi: The past, present, and future perspectives By Dr Hakim Djaballah and Bhavneet Bhinder Despite an investment of billions of US dollars in the search of novel therapies, cancer still remains the leading cause of death in the world. This emphasises the need… Read More
The CRISPR/Cas9 System: Cutting a path for rapid generation of more translational animal models. By Dr Kevin M. Gamber The recent high-profile translational failures in mouse models have highlighted the need for more relevant animal models. Advances in gene editing tools, including the CRISPR/Cas9 system, have enabled the… Read More
Library Logistics: Managing Comprehensive Compound Collections By Dr Jorg Kroll and David Booth Compound management may seem straightforward but in reality, as the number of new compounds increases dramatically year-on-year, the management of large collections has become increasingly challenging. A… Read More
Could The Keys To Precision & Personalised Medicine Be Rooted In Predictive Safety & Research Methods? By Robert G. Hunter To meet the massive challenges of future healthcare, perhaps no two facets hold greater promise than biomarkers for precision medicine and systems biology for personalised patient care. Read More
Long Live Peptides – Evolution of peptide half-life extension technologies and emerging hybrid approaches By Dr Ronald V. Swanson Among therapeutic modalities, peptides occupy a middle ground between traditional ‘small molecule’ drugs and the larger injectable biologics, not fitting comfortably into either category. Read More
Building New Models of Drug Discovery in Europe – The Innovative Medicines Initiative By Dr Angela Wittelsberger, Dr Hugh Laverty and Dr Michel Goldman The discovery and development of a new medicine is time-consuming, risky and expensive. It often takes 10-15 years and an investment of on average… Read More